ArticleJournal of cellular and molecular medicine2025
Oncogenic Role and Drug Resistance Effect of CCDC6 in iCCA: Potential Strategies for Targeted Intervention.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Oncogenic Role and Drug Resistance Effect of CCDC6 in iCCA: Potential Strategies for Targeted Intervention.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Intrahepatic cholangiocellular carcinoma (iCCA) is a digestive neoplasm with a very poor prognosis. This study examined the role of CCDC6 in the progression of iCCA and gemcitabine resistance through bioinformatics analysis and functional assays. Database analysis showed that CCDC6 was significantly overexpressed in iCCA, with its expression positively correlating with TNM stage and lymph node metastasis. Although its value as an independent prognostic biomarker was not statistically significant in survival analysis, its expression profile suggested potential as a therapeutic target. Functional experiments demonstrated that CCDC6 knockdown inhibited iCCA cell proliferation, migration and invasion in vitro in a dose-dependent manner, while overexpression enhanced these malignant phenotypes. Western blot analysis demonstrated that CCDC6 regulated epithelial-mesenchymal transition (EMT) by modulating Vimentin and Snail expression, promoting metastasis. In vivo xenograft and metastasis models confirmed that CCDC6 depletion significantly reduced tumour burden and lung metastases. Moreover, CCDC6 and the EMT marker Vimentin were upregulated in gemcitabine-resistant iCCA cells. γH2AX foci staining indicated that CCDC6 enhanced DNA damage repair (DDR), reducing chemotherapy-induced genomic instability, while CCDC6 inhibition exacerbated DNA damage, reversing resistance. These findings suggest CCDC6 drives chemoresistance through EMT activation and enhanced DDR, making it a promising therapeutic target in iCCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.